Farapulse

History

2020: Boston Scientific buys Farapulse

At the end of September, 2020 Boston Scientific announced signing of the contract on purchase of Farapulse company which specializes in development of the system of ablation by a pulse field for treatment of fibrillation of auricles and other cardiac arrhythmias.

Follows from the press release issued on the occasion of the conclusion of the transaction that patients with fibrillation of auricles which is suffered by more than 33 million people around the world often receive treatment in the form of antiarrhytmic medicines or warm ablation. Ablative therapy is a technique of power impact on the area of a myocardium responsible for violation of a warm rhythm.

Boston Scientific buys the developer of technologies for treatment of arrhythmia of Farapulse

The system of pulse therapy Farapulse is issued with the generator and catheters and provides ablation of heart fabric by creation of therapeutic electric field, but not at the expense of sources of thermal energy, such as radio-frequency ablation or cryoablation. This method is also called an irreversible elektroporation. It creates zones of ablation of heart fabric and by that interrupts the irregular electric signals capable to cause FP. According to developers, this technology pointwise puts the struck fabrics out of action, saving nearby fabrics from inadvertent ablation.

The selection Farapulse PFA technology is a promising new technique of warm ablation, including suitable for isolation of a pulmonary vein. Results of recent researches prove its efficiency, - the president and the CEO of Farapulse Allan Zingeler noted.

He also hoped that consolidation of the company with Boston Scientific will accelerate entry of the innovation system into the market and will provide access to it worldwide. But for a start a system should undergo reference clinical trial already under control of Boston Scientific.^[1]

Notes